Abstract
Introduction

Granulocyte-colony stimulating factor (G-CSF) is a polypeptide growth factor that plays a role in the basal regulation of neutrophil production. G-CSF is also used for haematopoietic stem cells (HSC)
Cellular Medicine 
• Introduction • The immunomodulation of G-CSF in adaptive immunity -G-CSF as a regulator of T cell responses -G-CSF as an inducer of tolerogenic dendritic cells (DC) -Mechanisms of action of G-CSF in immunomodulation -Therapeutic potential of G-CSF in autoimmune diseases • The neuroprotection of G-CSF in cerebral ischemia and neurodegeneration -The expression of G-CSF and G-CSF receptor in central nervous system -Penetration of the blood-brain barrier -Mechanisms of G-CSF in neuroprotection -G-CSF mobilizes haematopoietic stem cells to the injured brain -G-CSF activates anti-apoptotic pathway -G-CSF drives neuronal differentiation -G-CSF enhances angiogenesis -Evidence for neuroprotection of G-CSF • G-CSF-Bridge between immunomodulation and neuroprotection • Weighing G-CSF in immunomodulation and
The immunomodulation of G-CSF in adaptive immunity G-CSF as a regulator of T cell responses
There is compelling evidence that G-CSF, well known as the haematopoietic growth factor of the myeloid lineage [1] 
T cells results from CD45RO + memory T cells and from cells expressing the CD38 activation marker [2]. G-CSF not only alters T cell numbers, but also T cell functions through the shift of T cell subsets in both bone marrow and peripheral blood. G-CSF polarizes T cell differentiation from Th1 to Th2 cells and induces Th2 responses with the production of IL-4 and IL-10 [3-5], accompanied by a decrease in production of IFN-␥ and IL-2 [6], thereby suppressing T cell proliferative responses to allogeneic stimulation [5]. In addition, G-CSF increased the production of TGF-␤ [7, 8], and decreased the production of TNF-␣ [8]. Besides, G-CSF treatment elevates a CD4
G-CSF as an inducer of tolerogenic dendritic cells (DC)
G-CSF was reported to induce tolerogenic dendritic cells (DC2, plasmacytoid DC) in the peripheral blood of normal human recipients [3, 13, 14], thereby reflecting an important role of G-CSF for the induction and maintenance of peripheral tolerance. Administration of G-CSF to normal stem cell donors
Mechanisms of action of G-CSF in immunomodulation
G-CSF, like each of the other CSFs, exerts its biologic activities through binding to G-CSF-specific, high affinity receptor, which subsequently triggers multiple signalling mechanisms (Fig. 1) . In fact, G-CSF promotes neutrophil production and enhances neutrophil production and function by binding to its receptor [25] . The molecular mechanism by which G-CSF/G-CSF receptor signalling controls Th1 and Th2 differentiation as well as immune regulation is still poorly understood. It was reported that the T cellspecific transcription factor GATA-3 (GATA-3) was selectively expressed in Th2 cells, but not Th1 cells [26] . GATA-3 controls T helper cell differentiation, and directs to Th2 response [26, 27] [27] , directly activating the IL-5 promoter [26] and exhibiting enhancer activity for IL-4 gene expression [28] . 
Therapeutic potential of G-CSF in autoimmune diseases
In experimental models, G-CSF was shown to protect mice from graft-versus-host disease (GVHD) by orienting T cells to Th2 response [6] . G-CSF exhibited therapeutic potential in experimental autoimmune encephalomyelitis (EAE) [39, 40] [44] [45] [46] . In MS patients, a possible mechanism for G-CSF-related exacerbation is that G-CSF enhanced the adhesion of encephalitogenic T cells to extracellular matrix components [46] . [48] . It seems as if disease severity in EAE cannot be completely explained by the alterations of Th1-and Th2-derived cytokines from peripheral lymphocytes. G-CSF administration has also been shown to exacerbate collagen-induced arthritis (CIA) in mice [49] and passive-transfer model of CIA in rats [50] .
In RA patients, G-CSF exacerbated inflammatory joint disease by increasing the production and mobilization of myeloid lineage cells from the bone marrow and inducing the trafficking and local activation of these cells in peripheral tissues [47]. These aggravating effects of G-CSF were abrogated when G-CSF was administered together with cyclophosphamide or high-dosage corticosteroids. In SJL/J EAE mice with EAE induced by immunization with proteolipid protein 139-151 (PLP139-151), G-CSF administration caused worse clinical scores compared to controls not receiving G-CSF
Additionally, an unexpected modulation of disease severity was observed in a murine SLE model. [52] , thereby suggesting that it should be used with great caution in patients until these issues are resolved.
Chronic treatment of MRL-lpr/lpr mice with low dose of G-CSF (10 mg/kg) increased glomerular deposition of immunoglobulins and accelerated lupus disease, whereas high-dose treatment with G-CSF (200 mg/kg) prevented lupus nephritis by local downmodulation of FcgRIII expression within the glomeruli [51]. At lower dose, G-CSF seems to function as a key regulator of B cell homeostasis via the production of B cell-activating factor (BAFF), a novel member of the TNF ligand superfamily that is important for B cell maturation and antibody production. This novel finding might in part explain the occurrence of exacerbations of B cell-mediated autoimmune diseases in animal models and humans. Despite some setbacks in clinical application of G-CSF, it is clear that G-CSF plays an important role in the regulation of adaptive immunity. For example, G-CSF blockade in established CIA mice markedly reduced disease manifestations and was found be as effective as TNF blockade [47]. Taken together, G-CSF may have dual effects as an important anti-inflammatory or proinflammatory cytokine under different conditions
The neuroprotection of G-CSF in cerebral ischemia and neurodegeneration The expression of G-CSF and G-CSF receptor in central nervous system
Besides T cells and DC, other cell types also express G-CSF following appropriate stimulation or even in resting state, including vascular endothelial cells, fibroblasts and mesothelial cells. Within the CNS, G-CSF is expressed by neurons in all brain regions
including the hippocampus CA3 field, the hilus and subgranular zone of the dentate gyrus, the entorhinal cortex, the olfactory bulb, several cerebellar and brainstem nuclei where its receptor is expressed [53] . G-CSF receptor is also indeed expressed in dopaminergic neurons in the adult substantia nigra or mesencephalic cultures [54] [55] [56] . Besides in neurons, G-CSF is detected in astrocyte cultures after stimulation [57] [58] [59] [60] . However, Schneider et al. [53] [63] . Furthermore, an increase in G-CSF mRNA expression was not only seen in the ischemic lesion but also in the nonischemic frontal cortex after focal cerebral ischemia [63] . [53] . In the human, G-CSF was significantly increased in cerebrospinal fluid from patients with amyotrophic lateral sclerosis compared with controls, and expressed in reactive astrocytes [61] .
Similarly, there was a dramatic upregulation of G-CSF (more than 100-fold) elsewhere in the ipsilateral hemisphere 2 hrs after MCAO, and an accompanying induction of G-CSF in the contralateral hemisphere. At 6 hrs following ischemia, G-CSF expression became more clearly localized to the ischemic hemisphere, and, at 20 hrs of reperfusion, G-CSF expression was no longer detectable
The upregulation of G-CSF was accompanied by a more modest induction of the G-CSF receptor after cerebral ischemia, more prominent in the ipsilateral than the contralateral hemisphere [53] . [62] . We observed that G-CSF receptor was expressed in glial fibrillary acidic protein (GFAP) + astrocytes in ischemic regions, but not in non-ischemic regions (Fig. 2c, unpublished data) , revealing that G-CSF and its receptor likely function as an autocrine adaptive system within the CNS. [64] .
Immunohistochemistry demonstrated the co-expression and up-regulation of G-CSF and its receptor in neurons after MCAO and reperfusion. In human acute ischemic stroke, strong neuronal G-CSF receptor expression was encountered in the infarct area and the peri-infarct rim as compared to the contralateral cortex. In subacute infarctions, microglial G-CSF receptor predominated, whereas chronic infarction was characterized by the presence of G-CSF receptor-expressing reactive astrocytes
Penetration of the blood-brain barrier
Mechanisms of G-CSF in neuroprotection G-CSF mobilizes haematopoietic stem cells to the injured brain
Administration of G-CSF is known to mobilize HSC from the bone marrow into the peripheral blood (Fig. 3) [67] . Blockade of fibronectin in situ with an anti-fibronectin antibody dramatically decreased neurite outgrowth [75] , suggesting that fibronectin may play an important role in axon regeneration.
Fig. 3 Possible mechanisms for neuroprotection of G-CSF in cerebral ischemia and neurodegeneration. G-CSF provokes multiple intracellular signal transductions including Jak/Stat, ERK and PI3K/Akt in neuroprotection. (1) Anti-apoptosis: G-CSF mediates antiapoptotic pathway through ERK or/and JAK/Stat signalling activation and subsequent upregulation of bcl-2 and inhibition of caspase-3; (2) Neuronal differentiation: Stat regulates VEGF expression, or G-CSF activates endothelial cells to release BDNF. VEGF, BDNF and activated PI3K/Akt promote neurogenesis (3) Angiogenesis: G-CSF stimulates neutrophils or astrocytes to secrete VEGF, or directly mobilizes circulating endothelial progenitor cells (cEPCs) to promote angiogenesis within the CNS; and (4) The mobilization of autologous hemopoietic stem cells: G-CSF triggers the mobilization of autologous hemopoietic stem cells that migrate into ischemic brain, and thus significantly improve lesion repair.
Besides the increase of fibronectin, the numbers of brain-derived neurotrophic factor (BDNF)
+ cells in the marginal zone of the infarction were significantly increased in G-CSF-treated rats at 7, 14 and 21 days after ischemia compared to those of control rats [67] . (Fig. 2b) . [76] . [55] . [56] . [79] (Fig. 3) . [80] . [53] . [81] . In accordance with these observations, our previous studies reveal that nestin-positive cells were elevated in the marginal zone of the infarction of rats receiving G-CSF injection (Fig. 2e-A and B (Fig. 3) [82] , and establish a vascular niche that favours the proliferation of neuronal precursors [83] . Besides, Stat3 directly regulates vascular endothelial growth factor (VEGF) expression and hence angiogenesis in the adult brain [83, 84] , operating an autocrine VEGF loop in neurogenesis through reciprocal interaction with VEGF and Stat activation [80] . G-CSF also induces the activation of PI3K/Akt pathway [85] which is involved in neurogenesis [86] . The inhibition of endogenous Akt activity by the PI3K inhibitor LY294002_reduced_neuronal differentiation and generation [87] . [88] [90] . On the other hand, (Fig. 2e-C and D) . [94] . Administration of G-CSF reduced infarction volume [76, 89] and mortality rate was significantly reduced in animals treated with G-CSF compared with control animals [67] . G-CSFtreated experimental models showed a better functional recovery from 2 weeks through 5 weeks after ischemia compared to the cerebral ischemia-only controls [67, 89] . G-CSF given in the subacute phase (days 11 to 20) effectively improved not only motor performance but also higher brain function, compared with acute-phase treatment (days 1 to 10) [81] . [95] . Our results indicate that subcutaneous injection of G-CSF (10 g/kg per day) for 5 days decreased mortality rate, reduced infarction volume and improved neurological functions after cerebral ischemia [67] (Fig. 2a) . G-CSF not only decreased acute infarct volume in rats 4 hrs after onset of ischemia, but also improved recovery for a period of 10 days starting either 24 or 72 hrs after induction of ischemia, providing an experimental basis for application of G-CSF in the post-stroke recovery phase [96] .
Double fibronectin-and GFAP-positive cells indicate that astrocytes in ischemic regions may be a major source of fibronectin production (Fig. 2b). BDNFexpressing nestin-positive cells (Fig. 2b), possibly partially through synthesizing and releasing neurotrophic factors such as BDNF, could play an important role in recovery of neurological dysfunction. Although G-CSF treatment enhances the translocation of HSC into the ischemic brain and improves lesion repair, a recent report rebuts that G-CSF decreased the migration of bone marrow-derived cells and increased intrinsic microglia at the ischemic penumbra, suggesting that extrinsic cells are not involved in G-CSF-induced reduction of ischemic infarction
G-CSF activates anti-apoptotic pathway G-CSF protected neurons against cell apoptosis, which appears to be mediated via the neuronal G-CSF receptor, since antibody against G-CSF receptor was capable to abolish the protection [53]. G-CSF exerts its neuroprotective effect over direct activation of the anti-apoptotic pathway by up-regulating Stat3, pStat3 and Bcl-2 in transient focal ischemia in mice [76]. Another study also found that the neuroprotective role of G-CSF was manifested through the JAK/Stat signalling pathway and subsequent activation of Bcl-2 [77], in which overexpression of Bcl-2 protected against post-ischemic cerebral neuronal death [78]. Schabitz et al. showed that G-CSF receptor existed not only on haematopoietic cells but also on neurons and glial cells, and that the neuroprotective effect of G-CSF is dependent on G-CSF receptor-mediated activation of the JAK/Stat pathway [53]. Under OGD of human cerebral-neuroblastoma hybrid cell line, G-CSF prevented caspase-3 activation and subsequent cell death. We found that the expression of Bcl-2 (Fig. 2d) was up-regulated in hippocampal slice cultures exposed to G-CSF and the expression of MAP-2 (Fig. 2e-E and F) was increased in brain section from ischemic rats receiving G-CSF treatment, indicating that G-CSF-mediated neuron survival may be related to Bcl-2-madiated neuronal protection. In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neuron death, neuroprotection of G-CSF was mediated by increased Bcl-2 expression and decreased Bax expression
G-CSF also protected dopaminergic neurons against 6-hydroxydopamine (6-OHDA)-induced degeneration by activating the ERK pathway, but not the JAK/Stat pathway [56]. G-CSF-activated ERK signalling promoted cell survival via a dual mechanism by phosphorylating the pro-apoptotic protein Bad and by preventing 6-OHDA-induced Bcl-xL downregulation
G-CSF also down-regulated cytochrome C release to the cytosol, Bax translocation to the mitochondria and cleaved caspase-3 levels in neurons. The activation of the Stat3 pathway was accompanied by increased cIAP2 expression in glial cells. After MCAO and dopaminergic neuron damage, G-CSF treatment increased both neuronal and glial survival by effecting different anti-apoptotic pathways, which reflects the multifactorial actions of G-CSF in anti-apoptotic pathways
G-CSF drives neuronal differentiation Neuronal death after ischemia may involve a combination of apoptotic and necrotic processes even at the level of the individual neuron. This raises a question of how G-CSF induces a neuroprotective effect for apoptotic or necrotic neurons. It has been clarified that the adult mammalian forebrain harbours neuronal stem cells and neuronal progenitor cells in the anterior subventricular zone (SVZ), rostral migratory stream, olfactory bulb core and dentate gyrus (DG). However, G-CSF can induce bone marrow stem cells proliferation and mobilization, and activate endothelial cell proliferation, which may help to establish a vascular niche for neuronal stem cells
Importantly, G-CSF and its receptor were expressed in neurons of the SVZ and the DG [53]. G-CSF dosedependently induced activity of the promoter of the mature neuronal marker ␤-III-tubulin with a maximal induction greater than that reached by the most standard neuronal induction protocol, including markers for neuronal differentiation (␤-III-tubulin and neuronspecific enolase) and markers for mature glial cells (PLP and GFAP). G-CSF led to an increase in the population of cells expressing mature neuronal markers, indicating that G-CSF functions as regulator of the differentiation of adult neuronal stem cells
Administration of G-CSF in the subacute phase after cerebral infarction was effective for functional recovery through facilitating proliferation of intrinsic neuronal stem cells/progenitor cells
), suggesting that G-CSF may promote the differentiation of neuronal stem cells after ischemia/reperfusion lesion. Taken together with the recent evidence that G-CSF rescues dying neurons [53], G-CSF may potentially serve to promote brain recovery and repair by promoting the differentiation of neuronal stem cells. In addition, G-CSF enhanced the recruitment of progenitor cells from the lateral ventricular wall into the ischemic area of the neocortex and increased hippocampal neurogenesis not only in ischemic animals but also in the intact, non-ischemic region [53]. Based on this evidence, G-CSF may enhance structural repair and function even in healthy patients, and could offer a novel strategy for the treatment of patients with chronic stroke. Little is known regarding the possible role of G-CSF in the adult brain neurogenesis
G-CSF enhances angiogenesis One week after unilateral hindlimb ischemia, administration of G-CSF significantly increased the laser Doppler blood perfusion index, number of angiographically detectable collateral vessels, and capillary density
G-CSF augmented the differentiation of bone marrow-derived stromal cells into endothelial cells of blood vessels, resulting in early recovery of blood flow in the ischemic limbs [91]. These data clearly show that G-CSF modulates the recruitment and incorporation of circulating endothelial progenitor cells into ischemic tissue, which requires a coordinated multistep process including mobilization, chemoattraction, adhesion, transmigration and in situ differentiation. Recently, we also found that G-CSF can stimulate astrocytes to secrete VEGF that may promote angiogenesis within the CNS by paracrine pathway (data not published). Concomitant with an increase in neutrophil numbers in circulation, G-CSF increased plasma VEGF from neutrophils in vivo [92]. Blockade of the VEGF pathway abrogated G-CSF-induced angiogenesis, suggesting that G-CSF-induced angiogenesis is VEGF-dependent [92]. VEGF is an angiogenic protein with therapeutic potential in ischemic disorders, including stroke. The administration of VEGF to rats undergoing focal cerebral ischemia reduced infarct size and enhanced neurogenesis and cerebral angiogenesis via von Willebrand factor (vWF) staining [93]. In vivo experiments, our results show that administration of G-CSF enhanced the numbers of vWF-positive cerebral microvessels in the marginal zone of the infarction after ischemia/reperfusion lesion
Evidence for neuroprotection of G-CSF
Recent studies have shown the presence of G-CSF/ G-CSF-receptor system in the CNS, raising the possibility that G-CSF should have important nonhaematopoietic functions in the CNS. Growing evidence suggests that G-CSF plays a role in neuroprotection and neural tissue repair as well as in improving functional recovery
G-CSF injection showed a reduction in hemispheric atrophy at 35 days after cerebral ischemia and a significantly lower level of Evans blue dye extravasation compared to cerebral ischemia-only at 3 days, indicating a reduced BBB disruption [89]. G-CSF administration after transient ischemia also led to a decrease in the amount of edematous tissue present as measured by both structural magnetic resonance imaging (MRI) and brain water content
In [97] . Taken together, G-CSF offers some hope as therapy of stroke patients possibly through mobilization of endogenous stem cells [98] . Notably, a recent study reported that G-CSF treatment was only associated with transient early improvement in neurobehavioral outcomes after global ischemia complicated by mild hyperglycemia, but no long-term protection in global ischemia [99] .
Based on the expression of G-CSF receptor in dopaminergic neurons, G-CSF demonstrates a neuroprotective role in neurodegeneration. G-CSF protected against MPTP toxicity in PC12 cells and primary neuronal midbrain cultures in vitro [54] , against MPTP toxicity in older mice in vivo [54] and against MPTPinduced dopaminergic neuron death in a mouse model of Parkinson's disease [54, 55] . G-CSF also prevented dopaminergic neurons against 6-OHDAinduced degeneration [56] . In contrast, Henze [101] . A small beneficial effect of G-CSF on functional outcome after traumatic brain injury in adult mice was observed between G-CSF-treated and control groups [102] . [103, 104] (Fig. 4) 
G-CSF-Bridge between immunomodulation and neuroprotection
The inflammation within the CNS is a common phenomenon even in classic non
